Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

Feng, Y. Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,169

Identification of a major co-receptor for primary isolates of HIV-1

Deng, H., Liu, R., Ellmeier, W., Choe, S. S., Unutmaz, D., Burkhart, M. D., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,640

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,539

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C. S., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,173

CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1

Alkhatib, G., Combadière, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,703

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

Klatzmann, D., Champagne, É., Chamaret, S., Gruest, J., Guétard, D., Hercend, T., Gluckman, J. C., & Montagnier, L. (1984) · Nature · doi:10.1038/312767a0 · Cited by 2,435

Antibody neutralization and escape by HIV-1

Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421

The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates

Choe, H., Farzan, M., Sun, Y., Sullivan, N. J., Rollins, B. J., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G. J., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,286

Core Structure of gp41 from the HIV Envelope Glycoprotein

Chan, D. C., Fass, D., Berger, J. M., & Kim, P. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80205-6 · Cited by 2,000

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

Walker, L., Phogat, S., Chan-hui, P., Wagner, D., Pham, P., Goss, J. L., Wrin, T., Simek, M., Fling, S., Mitcham, J., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,849

Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints

Finn, J. A., Leman, J. K., Willis, J. R., Cisneros, A., Crowe, J. E., & Meiler, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154811 · Cited by 25

Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization

Phad, G. E., Bernat, N. V., Feng, Y., Ingale, J., Martinez-Murillo, P., O'Dell, S. J., Li, Y., Mascola, J. R., Sundling, C., Wyatt, R. T., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500122 · Cited by 24

HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization

Navis, M., Tran, K., Bale, S., Phad, G. E., Guenaga, J., Wilson, R., Soldemo, M., McKee, K., Sundling, C., Mascola, J. R., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004337 · Cited by 24

Identification and Characterization of a Broadly Cross-Reactive HIV-1 Human Monoclonal Antibody That Binds to Both gp120 and gp41

Zhang, M.-Y., Yuan, T., Li, J., Borges, A. R., Watkins, J. D., Guenaga, J., Yang, Z., Wang, Y., Wilson, R., Li, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044241 · Cited by 24

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response

Щербаков, Д. Н., Bakulina, A., Карпенко, Л. И., & Ilyichev, A. A. (2015) · Acta Naturae · doi:10.32607/20758251-2015-7-4-11-21 · Cited by 24

Saturation Mutagenesis of the HIV-1 Envelope CD4 Binding Loop Reveals Residues Controlling Distinct Trimer Conformations

Duenas-Decamp, M. J., Jiang, L., Bolon, D. N. A., & Clapham, P. R. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005988 · Cited by 24

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication

Richardson, S. I., Gray, E. S., Mkhize, N. N., Sheward, D. J., Lambson, B. E., Wibmer, C. K., Masson, L., Werner, L., Garrett, N., Passmore, J.-A. S., et al. (2015) · Retrovirology · doi:10.1186/s12977-015-0183-3 · Cited by 23

Efficiency of Bridging-Sheet Recruitment Explains HIV-1 R5 Envelope Glycoprotein Sensitivity to Soluble CD4 and Macrophage Tropism

O’Connell, O., Repik, A., Reeves, J. D., Gonzalez-Perez, M. P., Quitadamo, B., Anton, E. D., Duenas-Decamp, M. J., Peters, P. J., Lin, R., Zolla‐Pazner, S., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01834-12 · Cited by 23

A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization

Aw, R., McKay, P. F., Shattock, R. J., & Polizzi, K. M. (2018) · Protein Expression and Purification · doi:10.1016/j.pep.2018.03.013 · Cited by 23

Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages

Behrens, A., Kumar, A., Medina-Ramírez, M., Cupo, A., Marshall, K., Portillo, V. M. C., Harvey, D. J., Ozorowski, G., Zitzmann, N., Wilson, I. A., et al. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00639 · Cited by 22

A novel anti‐HIV‐1 bispecific bNAb‐lectin fusion protein engineered in a plant‐based transient expression system

Seber, L. E., Dent, M. W., Mahajan, G., Hamorsky, K. T., & Matoba, N. (2019) · Plant Biotechnology Journal · doi:10.1111/pbi.13090 · Cited by 22

IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus

Yin, L., Hou, W., Liu, L., Cai, Y., Wallet, M. A., Gardner, B., Chang, K.-F., Lowe, A., Rodriguez, C. A., Sriaroon, P., et al. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00373 · Cited by 22

Flow virometric sorting and analysis of HIV quasispecies from plasma

Musich, T., Jones, J. C., Keele, B. F., Jenkins, L. M. M., Demberg, T., Uldrick, T. S., Yarchoan, R., & Robert-Guroff, M. (2017) · JCI Insight · doi:10.1172/jci.insight.90626 · Cited by 21

Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library

Khan, L., Kumar, R., Thiruvengadam, R., Parray, H. A., Makhdoomi, M. A., Kumar, S., Aggarwal, H., Mohata, M., Hussain, A. W., Das, R., et al. (2017) · Scientific Reports · doi:10.1038/srep45163 · Cited by 21

MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency

Grupping, K., Selhorst, P., Míchiels, J., Vereecken, K., Heyndríckx, L., Kessler, P., Vanham, G. L., Martin, L., & Ariën, K. K. (2012) · Retrovirology · doi:10.1186/1742-4690-9-36 · Cited by 20

Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris

Aw, R., McKay, P. F., Shattock, R. J., & Polizzi, K. M. (2017) · AMB Express · doi:10.1186/s13568-017-0372-7 · Cited by 20

A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1

Gach, J. S., Quendler, H., Tong, T., Narayan, K. M., Du, S. X., Whalen, R. G., Binley, J. Μ., Forthal, D. N., Poignard, P., & Zwick, M. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072054 · Cited by 19

Functional and Highly Cross-Linkable HIV-1 Envelope Glycoproteins Enriched in a Pretriggered Conformation

Nguyen, H. T., Qualizza, A., Anang, S., Zhao, M., Zou, S., Zhou, R., Wang, Q., Zhang, S., Deshpande, A. A., Ding, H., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01668-21 · Cited by 16

Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein

van Schooten, J., Farokhi, E., Schorcht, A., van den Kerkhof, T. L. G. M., Gao, H., van der Woude, P., Burger, J. A., Meesters, T. G. R., Bijl, T. P. L., Ghalaiyini, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32208-0 · Cited by 19

Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

Wen, Y., Trinh, H. V., Linton, C. E., Tani, C., Norais, N., Martinez-Guzman, D., Ramesh, P., Sun, Y., Situ, F., Karaca-Griffin, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194266 · Cited by 19

Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States

Heredia, J. D., Park, J., Choi, H. S. J., Gill, K. S., & Procko, E. (2019) · Journal of Virology · doi:10.1128/jvi.00219-19 · Cited by 17

Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors

Narayanan, K. K., & Procko, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.636660 · Cited by 18

Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies

Carbonetti, S., Oliver, B. G. G., Glenn, J. A., Stamatatos, L., & Sather, D. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086905 · Cited by 18

The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage

Zhou, J. O., Zaidi, H. A., Ton, T., & Fera, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01529 · Cited by 18

Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate

Narayan, K. M., Agrawal, N., Du, S. X., Muranaka, J., Bauer, K., Leaman, D. P., Phung, P., Limoli, K. L., Chen, H., Boenig, R. I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052732 · Cited by 17

An HIV-1 Env–Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes

Chen, Y., Wilson, R., O'Dell, S. J., Guenaga, J., Feng, Y., Tran, K., Chiang, C.-I., Arendt, H. E., DeStefano, J., Mascola, J. R., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601134 · Cited by 16

Humanized Immunoglobulin Mice

Verkoczy, L. K. (2017) · Advances in immunology · doi:10.1016/bs.ai.2017.01.004 · Cited by 17

From antiretrovirals to curative therapies: Current developments in HIV treatment and prevention

Mundlia, P., Sharma, A., Kaur, J. K., Chaubey, B., Ranawat, P., Sood, V., Pandey, A., Singh, G., & Barnwal, R. P. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118190 · Cited by 21

N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03

Wang, W., Zirkle, B., Nie, J., Ma, J., Gao, K., Chen, X. S., Huang, W., Kong, W., & Wang, Y. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000595 · Cited by 16

Neutralizing Antibodies Inhibit HIV-1 Infection of Plasmacytoid Dendritic Cells by an FcγRIIa Independent Mechanism and Do Not Diminish Cytokines Production

Lederle, A., Su, B., Holl, V., Penichon, J., Schmidt, S., Decoville, T., Laumond, G., & Moog, C. (2014) · Scientific Reports · doi:10.1038/srep05845 · Cited by 17

Converging on an HIV Vaccine

Korber, B., & Gnanakaran, S. (2011) · Science · doi:10.1126/science.1211919 · Cited by 16

Protein engineering strategies for the development of viral vaccines and immunotherapeutics

Koellhoffer, J. F., Higgins, C. D., & Lai, J. R. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.10.014 · Cited by 16

Plant made anti-HIV microbicides—A field of opportunity

Lotter-Stark, T., Rybicki, E. P., & Chikwamba, R. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.06.002 · Cited by 16

Topological Analysis of HIV-1 Glycoproteins Expressed In Situ on Virus Surfaces Reveals Tighter Packing but Greater Conformational Flexibility than for Soluble gp120

Tong, T., Osawa, K., Robinson, J. E., Crooks, E. T., & Binley, J. Μ. (2013) · Journal of Virology · doi:10.1128/jvi.01145-13 · Cited by 15

Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11

Moyo-Gwete, T., Ereño‐Orbea, J., Jacob, R. A., Pavillet, C. E., Kariuki, S. M., Tangie, E., Julien, J., & Dorfman, J. R. (2018) · Journal of Virology · doi:10.1128/jvi.02261-17 · Cited by 13

Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China

Nie, J., Wang, W., Wen, Z., Song, A., Hong, K., Lu, S., Zhong, P., Xu, J., Kong, W., Li, J., et al. (2012) · Journal of Virological Methods · doi:10.1016/j.jviromet.2012.07.011 · Cited by 14

Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy

MOFENSON, L. M. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318235517e · Cited by 14

Passive Immunization against HIV/AIDS by Antibody Gene Transfer

Yang, L., & Wang, P. (2014) · Viruses · doi:10.3390/v6020428 · Cited by 14

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01

Ojeda, E. F. C., & Perelson, A. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710012 · Cited by 15

The Relative Positioning of B and T Cell Epitopes Drives Immunodominance

Biavasco, R., & Giovanni, M. D. (2022) · Vaccines · doi:10.3390/vaccines10081227 · Cited by 13

Signature Biochemical Properties of Broadly Cross-Reactive HIV-1 Neutralizing Antibodies in Human Plasma

Sajadi, M. M., Lewis, G. K., Seaman, M. S., Guan, Y., Redfield, R., & DeVico, A. L. (2012) · Journal of Virology · doi:10.1128/jvi.06547-11 · Cited by 13

Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins

Bruun, T., Grassmann, V., Zimmer, B., Asbach, B., Peterhoff, D., Kliche, A., & Wagner, R. (2017) · mAbs · doi:10.1080/19420862.2017.1364824 · Cited by 13

Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody

Heydarchi, B., Fong, D., Gao, H., Salazar-Quiroz, N. A., Edwards, J. M., Gonelli, C. A., Grimley, S. L., Aktepe, T. E., Mackenzie, C., Wales, W. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100635 · Cited by 12

Efficiency of Neutralizing Antibodies Targeting the CD4-Binding Site: Influence of Conformational Masking by the V2 Loop in R5-Tropic Clade C Simian-Human Immunodeficiency Virus

Watkins, J. D., Diaz-Rodriguez, J., Siddappa, N. B., Corti, D., & Ruprecht, R. M. (2011) · Journal of Virology · doi:10.1128/jvi.05994-11 · Cited by 12

Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies

Mohan, T., Berman, Z., Kang, S., & Wang, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-25960-1 · Cited by 12

Development and Characterization of Monoclonal Antibodies to the 32 kDa Viral Attachment Protein of Lymphocystis Disease Virus and Their Neutralizing Ability in Vitro

Zhong, Y., Tang, X., Sheng, X., Xing, J., & Zhan, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092536 · Cited by 12

Broadly neutralizing antibodies for therapy of viral infections

Varadarajan, R., Srinivasan, S., Maity, S., & Ghosh, M. (2016) · Antibody Technology Journal · doi:10.2147/anti.s92190 · Cited by 11

Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists

Hikichi, Y., Yokoyama, M., Takemura, T., Fujino, M., Kumakura, S., Maeda, Y., Yamamoto, N., Sato, H., Matano, T., & Murakami, T. (2016) · Journal of General Virology · doi:10.1099/jgv.0.000536 · Cited by 11

Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein

Nguyen, H. T., Madani, N., Ding, H., Elder, E., Princiotto, A. M., Gu, C., Darby, P., Alin, J., Herschhorn, A., Kappes, J. C., et al. (2017) · Virology Journal · doi:10.1186/s12985-017-0704-x · Cited by 11

Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies

Miller, N. L., Raman, R., Clark, T., & Sasisekharan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904609 · Cited by 12

Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies

Moyo-Gwete, T., Ferreira, R.-C., Davids, R., Sonday, Z., Moore, P. L., Travers, S. A. A., Wood, N. T., & Dorfman, J. R. (2016) · Virology · doi:10.1016/j.virol.2016.10.026 · Cited by 11

Public antibodies: convergent signatures in human humoral immunity against pathogens

Rao, V. N., & Coelho, C. H. (2025) · mBio · doi:10.1128/mbio.02247-24 · Cited by 10

A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV

Sajadi, M. M., Abbasi, A., Tehrani, Z. R., Siska, C. C., Clark, R. H., Chi, W., Seaman, M. S., Mielke, D., Wagh, K., Liu, Q., et al. (2025) · Structure · doi:10.1016/j.str.2025.04.016 · Cited by 11

HIV Broadly Neutralizing Antibodies: VRC01 and Beyond

Wu, X. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0484-2_3 · Cited by 10

Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach

Li, J., Nikanjam, M., Cunningham, C. K., McFarland, E. J., Coates, E. E., Houser, K. V., Lin, B. C., McDermott, A. B., Flach, B., Gama, L., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2026 · Cited by 10

CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants

Dreja, H. S., Pade, C., Chen, L., & McKnight, Á. (2015) · Journal of General Virology · doi:10.1099/vir.0.000120 · Cited by 10

Antibodies: From novel repertoires to defining and refining the structure of biologically important targets

Conroy, P. J., Law, R. H. P., Caradoc-Davies, T. T., & Whisstock, J. C. (2017) · Methods · doi:10.1016/j.ymeth.2017.01.003 · Cited by 12

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen

Vijayan, A., García‐Arriaza, J., Raman, S. C., Conesa, J. J., Chichón, F. J., Santiago, C. A., Sorzano, C. Ó. S., Carrascosa, J. L., & Estéban, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133595 · Cited by 9

Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State

Zhang, P., Kwon, A. L., Guzzo, C., Liu, Q., Schmeisser, H., Miao, H., Lin, Y., Cimbro, R., Huang, J., Connors, M., et al. (2021) · mBio · doi:10.1128/mbio.00090-21 · Cited by 9

Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

Utachee, P., Isarangkura-na-ayuthaya, P., Tokunaga, K., Ikuta, K., Takeda, N., & Kameoka, M. (2014) · Retrovirology · doi:10.1186/1742-4690-11-32 · Cited by 9

Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture

Liang, G., Madhavarao, C. N., Morris, C. S., O’Connor, T., Ashraf, M., & Yoon, S. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13110-9 · Cited by 8

Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains

Radford, C. E., & Bloom, J. D. (2025) · Journal of Virology · doi:10.1128/jvi.00195-25 · Cited by 8

Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques

Morris, D. J., Gorman, J., Zhou, T., Lora, J., Connell, A. J., Li, H., Liu, W., Roark, R. S., Campion, M. S., Carey, J. W., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115848 · Cited by 8

A streamlined cloning workflow minimising the time-to-strain pipeline for Pichia pastoris

Royle, K. E., & Polizzi, K. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-16172-0 · Cited by 8

Design, display and immunogenicity of HIV1 gp120 fragment immunogens on virus-like particles

Purwar, M., Pokorski, J. K., Singh, P., Bhattacharyya, S., Arendt, H. E., DeStefano, J., LaBranche, C. C., Montefiori, D. C., Finn, M. G., & Varadarajan, R. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.032 · Cited by 7

Display of the HIV envelope protein at the yeast cell surface for immunogen development

Mathew, E., Hong, Z., Connelly, S. M., Sullivan, M. A., Brewer, M. G., Piepenbrink, M. S., Kobie, J. J., Dewhurst, S., & Dumont, M. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205756 · Cited by 8

The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies

Duenas-Decamp, M. J., O’Connell, O., Corti, D., Zolla‐Pazner, S., & Clapham, P. R. (2012) · Retrovirology · doi:10.1186/1742-4690-9-9 · Cited by 8

Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1

Cassidy, T., Stephenson, K. E., Barouch, D. H., & Perelson, A. S. (2024) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011518 · Cited by 8

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance

Cohen, P., Lambson, B. E., Mkhize, N. N., Moodley, C., Yssel, A., Moyo-Gwete, T., York, T., Gwashu-Nyangiwe, A., Ndabambi, N., Thebus, R., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01730-24 · Cited by 7

A Mammalian Cell Based FACS-Panning Platform for the Selection of HIV-1 Envelopes for Vaccine Development

Bruun, T., Mühlbauer, K., Benen, T. D., Kliche, A., & Wagner, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109196 · Cited by 7

Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection

Shipley, M. M., Prasad, V. M., Doepker, L. E., Dingens, A. S., Ralph, D., Harkins, E., Dhar, A., Arenz, D., Chohan, V., Weight, H., et al. (2021) · eLife · doi:10.7554/elife.68110 · Cited by 7

Identification of a novel HIV-1-neutralizing antibody from a CRF07_BC-infected Chinese donor

Sun, Y., Qiao, Y., Zhu, Y., Chong, H., & He, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18594 · Cited by 7

Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity

Zhang, D., Zou, S., Hu, Y., Hou, J., Hu, X., Ren, L., Ma, L., He, X., Shao, Y., & Hong, K. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01096 · Cited by 7

HIV-1 gp120–CD4-Induced Antibody Complex Elicits CD4 Binding Site–Specific Antibody Response in Mice

Galkin, A. G., Chen, Y., Guenaga, J., O'Dell, S. J., Acevedo, R., Steinhardt, J. J., Wang, Y., Wilson, R., Chiang, C.-I., Doria‐Rose, N. A., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901051 · Cited by 7

Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization

Aljedani, S., Liban, T. J., Tran, K., Phad, G. E., Singh, S., Dubrovskaya, V., Pushparaj, P., Martinez-Murillo, P., Rodarte, J. V., Mileant, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009543 · Cited by 7

Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques

Gao, N., Gai, Y., Meng, L., Wang, C., Zhang, X., Wang, W., Qin, C., Yu, X., & Gao, F. (2020) · Viruses · doi:10.3390/v12020163 · Cited by 7

Partial compartmentalisation of HIV-1 subtype C between lymph nodes, peripheral blood mononuclear cells and plasma

Jeewanraj, N., Mandizvo, T., Mulaudzi, T., Gumede, N., Ndhlovu, Z. M., Ndung’u, T., Gounder, K., & Mann, J. K. (2023) · Virology · doi:10.1016/j.virol.2023.03.011 · Cited by 6

Pediatric immunotherapy and HIV control

Chinunga, T. T., Chahroudi, A., & Ribeiro, S. P. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000857 · Cited by 6

Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

Ringe, R. P., Das, L., Choudhary, I., Sharma, D., Paranjape, R., Chauhan, V. S., & Bhattacharya, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046713 · Cited by 6

Receptor Binding Domain Based HIV Vaccines

Liu, H., Bi, W., Wang, Q., Lu, L., & Jiang, S. (2015) · BioMed Research International · doi:10.1155/2015/594109 · Cited by 6

Genetic and Phenotypic Analysis of CRF01_AE HIV-1 env Clones from Patients Residing in Beijing, China

Chen, D., He, X., Ye, J., Zhao, P., Zeng, Y., & Feng, X. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0377 · Cited by 6

Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120

Qiao, Y., Man, L., Qiu, Z., Yang, L., Sun, Y., & He, Y. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.013 · Cited by 6

Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FI T45

Falkenhagen, A., & Joshi, S. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.017 · Cited by 6

A 2–4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01

Tachibana, S., Sasaki, M., Tanaka, T., Inoue, M., Ophinni, Y., Kotaki, T., & Kameoka, M. (2017) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2017.0063 · Cited by 6

Molecular imaging of viral pathogenesis and opportunities for the future

Kelly, B., Boudreau, J. E., Beyea, S., & Brewer, K. (2025) · npj Imaging · doi:10.1038/s44303-024-00056-w · Cited by 5

Rapid production of HIV-1 neutralizing antibodies in baculovirus infected insect cells

Liu, B., Wang, R., Wu, F., Xu, X., & Chen, H. (2014) · Protein Expression and Purification · doi:10.1016/j.pep.2014.04.004 · Cited by 5

AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition

Singh, A., Permar, S. R., Kollmann, T. R., Levy, O., Marovich, M., & Paris, K. D. (2019) · mSphere · doi:10.1128/msphere.00320-19 · Cited by 5

Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies

Shivatare, S. S., Cheng, T.-J. R., Cheng, Y., Shivatare, V. S., Tsai, T.-I., Chuang, H.-Y., Wu, C., & Wong, C. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00375 · Cited by 5

Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection

Ndlovu, B., Gounder, K., Muema, D., Raju, N., Hermanus, T., Mthethwa, Q., Robertson, K., Walker, B. D., Georgiev, I. S., Morris, L., et al. (2020) · Virology · doi:10.1016/j.virol.2020.03.003 · Cited by 5

Effect of different cell culture media on the production and glycosylation of a monoclonal antibody from a CHO cell line

Lee, J., Ortega‐Rodriguez, U., Madhavarao, C. N., Ju, T., O’Connor, T., Ashraf, M., & Yoon, S. (2025) · Cytotechnology · doi:10.1007/s10616-025-00733-7 · Cited by 4

Cell‐to‐cell transmission of HIV‐1 from provirus‐activated cells to resting naïve and memory human primary CD4 T cells is highly efficient and requires CD4 and F‐actin but not chemokine receptors

Lan, J., Li, W., Yu, R., Syed, F., & Yu, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28005 · Cited by 4

Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVCEnv) covalently complexed to two-domain CD4S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits

Tumba, N. L., Owen, G. R., Killick, M. A., & Papathanasopoulos, M. A. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100222 · Cited by 4

Targeting Glycans of HIV Envelope Glycoproteins for Vaccine Design

Behrens, A., Seabright, G. E., & Crispin, M. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623823-00300 · Cited by 4

Human Antibody Discovery Platforms

Strohl, W. R. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch5 · Cited by 4

Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response

Singh, S., Kumar, S., & Luthra, K. (2026) · Journal of Virology · doi:10.1128/jvi.02202-25 · Cited by 3

Stabilization of Outer Domain of gp120 from HIV-1 Subtype C for Vaccine Immunogen Design

Thompson, J., Kumar, P., Yi, J., Bowder, D., Wood, C. A., & Xiang, S.-H. (2015) · Procedia in Vaccinology · doi:10.1016/j.provac.2015.05.002 · Cited by 3

Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B′ subtype infected individual with broadly neutralization activity

Zhang, D., Liu, Z., Wang, W., Chen, M., Hou, J., Zhang, Z., Ren, W., Ren, L., & Hao, Y. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.02.021 · Cited by 3

HIV-1 Membrane-Proximal External Region Fused to Diphtheria Toxin Domain-A Elicits 4E10-Like Antibodies in Mice

Zhang, Z., Wei, X., Lin, Y., Huang, F., Shao, J., Qi, J., Deng, T., Li, Z., Gao, S., Li, S., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.07.004 · Cited by 3

In vitro and In vivo Resistance to Human Immuno Deficiency Virus Type 1 Entry Inhibitors

Maeda, Y. (2012) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.s2-004 · Cited by 3

Mapping essential somatic hypermutations in a CD4-binding site bNAb informs HIV-1 vaccine design

Dam, K.-M. A., Gristick, H. B., Li, Y. E., Yang, Z., Gnanapragasam, P. N. P., West, A. P., Seaman, M. S., & Björkman, P. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115713 · Cited by 2

SEE PROFILE

Zhou, T., Xu, L., Yang, Y., & Nussenzweig, M. C. (2016)

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Zhou, T., Georgiev, I. S., Wu, X., Yang, Z., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,123

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Wu, X., Yang, Z., Li, Y., Högerkorp, C., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,724

P09-05. Mechanism of HIV-1 resistance to a monoclonal antibody that effectively targets the site of CD4 attachment

Wu, X., Zhou, T., O'Dell, S. J., Wyatt, R. T., Kwong, P. D., & Mascola, J. (2009) · Retrovirology · doi:10.1186/1742-4690-6-s3-p118

Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment

Wu, X., Zhou, T., O'Dell, S. J., Wyatt, R. T., Kwong, P. D., & Mascola, J. R. (2009) · Journal of Virology · doi:10.1128/jvi.01142-09 · Cited by 94